tbuckley/cabot-search huggingface dataset:
AB1154 NEW INFLAMMATION PARAMETERS IN PSORIATIC ARTHRITIS: NEUTROPHIL/LYMPHOCYTE AND PLATELET/LYMPHOCYTE RATIOS
Authors: A. Ben Amou, S. Rahmouni, H. Tbini, K. Zouaoui, S. Rekik, S. Boussaid, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Monitoring disease activity in patients with psoriatic arthritis (PsA) is crucial. Commonly used inflammation markers, including C-reactive protein (CRP), lack specificity and sensitivity. Other markers using complete blood count (CBC) parameters have been proposed: neutrophil/lymphocyte ratios (NLR), platelet/lymphocyte ratios (PLR). <h3>Objectives</h3> The aim of this study is to investigate these ratios in PsA. <h3>Methods</h3> A cross-sectional study including patients with PsA meeting CASPAR criteria. Socio-demographic, clinical and biological data were collected. NLR and PLR ratios were calculated from the CBC parameters. <h3>Results</h3> Thirty-seven patients were enrolled; the sex ratio M/F was 2.1. The mean age was 52.46±14.22 years, the mean age at symptoms onset was 41.32±14.69 years. Axial and peripheral involvement were noted in 21 and 31 cases, respectively. Rheumatoid factor, ACPA and ANA were positive in 10, 8 and 9 cases, respectively. At least one extra-articular manifestation was present in 18 cases. Hip involvement was noted in 11 cases. The mean CRP was 31.63±37.95 mg/L. The mean DAS28-CRP, BASDAI, ASDAS-CRP and DAPSA were 4.06±1.54, 5.06±6.14, 2.60±1.05 and 38.31±35.05, respectively. The mean values for leukocytes, neutrophils, and lymphocytes were 10.97±12.95 10<sup>3</sup>/mm3, 5.22±2.04 10<sup>3</sup>/mm3, and 2.36±0.96 10<sup>3</sup>/mm3, respectively. The mean hemoglobin level was 12.73±1.57 g/dl. The mean platelet count was 315.03±119.01 10<sup>3</sup>/mm3. The mean NLR and PLR were 2.52±1.31 and 58.05±91.69, respectively. Our statistical study identified a correlation of PLR with CRP (r=0.423; p=0.016), hemoglobin level (r=-0.524; p=0.002) and DAPSA (r=0.487; p=0.047). However, no correlation was found between PLR and age, disease chronology, axial or peripheral involvement, immunological profile, extra-articular manifestations, DAS28-CRP, BASDAI, ASDAS-CRP, and hip involvement. Furthermore, no correlation between NLR and any of the above variables was identified. <h3>Conclusion</h3> This study showed that PLR correlates with CRP, hemoglobin level, and disease activity. These new, inexpensive, and available inflammation markers may be useful in monitoring patients with PsA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1149 SEX DISTRIBUTION IN PSORIATIC ARTHRITIS: SYSTEMATIC LITERATURE REVIEW
Authors: B. Firlatan, G. S. Kart Bayram, G. Ayan, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The prevalence of psoriatic arthritis (PsA) is considered equal in male and female patients but recent studies in cohorts of PsA it has been observed that women are more dominant in sex distribution, and the female-male ratio varies between 1.2 and 2 [1]. It is not yet clear whether this is related to a change in the epidemiology of the disease. <h3>Objectives</h3> To assess the female-male ratios in recent PsA studies. <h3>Methods</h3> A systematic review of the literature (from January 2020 to September 2022) was performed using the Pubmed database with keywords and MeSH terms referring to psoriatic arthritis. Randomized controlled, cross-sectional, prospective, and retrospective cohort studies involving ≥20 patients and specifying the number of men and women were considered eligible. Only original articles in English were included. Two independent reviewers performed study selection and data collection. The number of female and male patients, study design, study center, and PsA clinical phenotypes were recorded. <h3>Results</h3> Total of 1469 articles were selected for full-text reading, of which 486 were included for analyses. Overall, the number of studies in which the F/M and M/F ratio ≥1.5 was 86 (17.7%) and 60 (12.4%), respectively. Comparing the study types, it was observed that the female gender was more dominant in cross-sectional studies (p=0.004), Table 1. The sex distribution was more heterogeneous in single-center studies than in multi-center studies. Studies were stratified according to continents; it was found that the number of studies in which the F/M ratio is ≥1.5 was higher in America than the multinational studies (27% vs. 4%). On the other hand, the studies from Asia had higher male predominance. <h3>Conclusion</h3> Although there were some differences observed in sex distribution by study design and continents, overall, the ratio of females to males was similar. The female predominance observed in some studies might be due to selection bias or greater access to the medical system. <h3>Reference</h3> [1]Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513-26. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1001 PROPOSAL OF SIMPLIFIED CT SYNDESMOPHYTE SCORE (SCTSS) AND COMPARISON WITH CTSS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Authors: H. R. Kim, H. K. Min, S. H. Lee
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The CT syndesmophyte score (CTSS) can evaluate spinal progression more precisely than mSASSS in ankylosing spondylitis (AS); however, it is complex and time consuming. <h3>Objectives</h3> Here, we propose a simplified CTSS (sCTSS) for measuring spinal structural changes in AS. <h3>Methods</h3> Patients with AS were recruited from a single tertiary hospital. Baseline and 2-year follow-up whole spine CT images were used to calculate CTSS and sCTSS. The sCTSS used the anterior and posterior vertebral corners, and ranged 0–184. Intraclass correlation coefficients (ICC) were calculated, as well as the smallest detectable changes. <h3>Results</h3> Fifty AS patients were included. For reader 1, the mean sCTSS at baseline and 2-year follow-up were 11.7 ± 14.6 and 15.8 ± 16.1, whereas those for reader 2 were 12.0 ± 12.5 and 15.8 ± 15.7, respectively. The ICCs for CTSS at baseline and at 2-year follow-up were 0.97 (95% confidence interval [CI] 0.96–0.99) and 0.98 (0.97–0.99), respectively, and that for changes over the 2 years was 0.48 (95% CI 0.23–0.67). For sCTSS, the ICCs were 0.96 (95% CI 0.92–0.97), 0.97 (95% CI 0.94–0.98), and 0.58 (95% CI 0.36–0.74), respectively. Detection rates for syndesmophyte progression were comparable between CTSS and sCTSS. The detection rate for syndesmophytes on only lateral side was 13.2 and 11.4%, and 11.4 and 15.2% at baseline and 2-year follow-up (reader 1 and 2). <h3>Conclusion</h3> sCTSS and CTSS showed similar detection rates for syndesmophyte progression. sCTSS may be a reliable method for evaluating spinal structural damage in AS. <h3>References</h3> [1]de Bruin, F. et al. Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Ann Rheum Dis 77, 371-377 (2018). [2]de Koning, A. et al. Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. Ann Rheum Dis 77, 293-299 (2018). [3]Tan, S. et al. Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim. Ann Rheum Dis 75, 1951-1957 (2016). <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1106 EFFICACY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS:A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: H. Zhou, G. M. Xia, C. Su, H. Y. Tian, Y. J. Deng, X. M. Wang, J. Y. Ren, R. T. Shen, Q. Y. Su, Q. Yu, P. F. He, X. Li, S. X. Zhang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriatic arthritis (PsA) is a chronic autoimmune disease that is seen in nearly 30% of patients with psoriasis. As a new targeted treatment drug, risanzumab may provide a new treatment with fewer side effects for patients with psoriasis arthritis. However, there are currently discrepancies in the evaluation of the efficacy of Risankizumab in PsA patients. <h3>Objectives</h3> This study aims to systematically evaluate the efficacy of Risankizumabin patients with PsA. <h3>Methods</h3> We systematically searched PubMed, Embase, Web of Science, Cochrane Library, MEDLINE, Web of Knowledge, Clinical Trials. gov, FDA. gov and print databases (SSRN, bioRxiv, and MedRxiv) from the establishment of the database to January 2, 2023, and conducted data analysis in Stata 12.0. We used the I-squared (I2) to assess the heterogeneity of the included studies in order to select the appropriate model for statistical analysis. A random-effects model will be used when I2&gt;50%, otherwise, a fixed-effect model will be applied. The publication bias was evaluated by using Egger test. <h3>Results</h3> We ultimately included 11 studies that included data on six outcome indexes. The results of the meta-analysis of ACR20 as our main outcome indicator of interest showed patients in the Risankizumab group had a significantly higher ACR20 response rate than those in the placebo group at 24 weeks [RR=1.768, 95%CI (1.572, 1.988), P&lt;0.001]. In addition, compared with the placebo group, the MDA response rate of Risankizumab group significantly higher [RR=1.841, 95%CI 1.084-3.126, P&lt;0.05]. Then, SF-36 score [SMD=0.508, 95%CI (0.337, 0.678), P&lt;0.001] were improved in the Risankizumab group, which was statistically significantly different from the placebo group. For HAQ-DI, the Risankizumab group had significantly lower scores than the placebo group[SMD=-0.273, 95%CI (0.373, 0.172), P&lt;0.001]. However, FACIT-F scores in the Risankizumab group were significantly higher than placebo group [SMD=0.270, 95%CI (0.177, 0.364), P&lt;0.001]. For PASI, patients had an average reduction of 9.8 points after Risankizumab treatment [MD=-9.832, 95%CI (14.367, 5.298), P&lt;0.001]. (Figure 1) <h3>Conclusion</h3> The overall results of the meta-analysis show that Risankizumab treatment can significantly improve the symptoms of PsA such as arthritis and skin symptoms, improve the clinical remission rate and the quality of life of patients. However, taking Risankizumab may also potentially increase fatigue levels in patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1055 COMORBIDITIES IN SPONDYLOARTHRITIS: DATA FROM THE MOROCCAN RBSMR REGISTRY
Authors: Z. Baba, A. Mougui, R. Abouqal, F. Allali, R. Bahiri, A. Bezza, A. EL Maghraoui, I. El Ghozlani, T. Harzy, H. Hassikou, I. Hmamouchi, I. Linda, S. Janani, R. Niamane, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In addition to the extra-articular manifestations associated with spondyloarthritis such as IBD, psoriasis and uveitis, spondyloarthritis is linked to an increased risk of comorbidities. <h3>Objectives</h3> To study the prevalence of comorbidities in spondyloarthritis (SPA) at inclusion and 36-month follow-up and their influence on disease activity and functional outcome in a cohort of patients followed for SPA from the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). <h3>Methods</h3> Data were analyzed from cohort of 194 patients with SPA from the RBSMR Registry including comorbidities (hypertension, diabetes, dyslipidemia, obesity, osteoporosis, sedentary lifestyle, gastrointestinal ulcer, smoking, depression, fibromyalgia) and disease activity scores at inclusion (M0) and at 36-month follow-up (M36). <h3>Results</h3> The mean age was 40,23 ± 13,68 ans. The sex-ratio (M/W) was 1,73. 96.4 % of the patients had axial involvement, 70 % had peripheral involvement and 61.5 % had enthesitis. SPA was radiographic in 88.1 % of the cases. The mean duration of disease was 615,90 ± 349,12 weeks. 57,2% of patients had at least one comorbidity, among whom the median comorbidity count was 1 (range 1-5). <h3>Conclusion</h3> In our study, the presence of comorbidities was correlated with more severe disease activity. Better management of these comorbidities may result in better outcome of patients with SPA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1139 ASSOCIATION BETWEEN TRIGLYCERIDE‑GLUCOSE INDEX AND CAROTID ATHEROSCLEROSIS IN PATIENTS WITH PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY
Authors: W. Xie, Z. Zhang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The triglyceride-glucose (TyG) index, proposed as a surrogate marker for insulin resistance, appeared to be a good indicator of clinically overt cardiovascular events and subclinical atherosclerosis in general population. <h3>Objectives</h3> We aimed to investigate the correlation of TyG index with atherosclerotic risk among patients with psoriatic arthritis (PsA). <h3>Methods</h3> This cross-sectional study included 165 consecutive PsA patients receiving carotid ultrasonography with integrated TyG index, calculated as ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2]. Logistic regression models were applied to analyze the association of TyG index as continuous variables and tertiles with carotid atherosclerosis and carotid artery plaque. <h3>Results</h3> Overall, PsA patients with carotid atherosclerosis had substantially higher TyG index than those without (8.82±0.50 vs. 8.54±0.55, p=0.002). The frequency of carotid atherosclerosis was increased with increases in TyG index tertiles, showing 14.8%, 34.5%, 44.6% for tertile 1, 2 and 3, respectively (p=0.003). Multivariate logistic analyses showed that each 1-unit increase in TyG index was significantly associated with prevalent carotid atherosclerosis (unadjusted OR 2.65 [1.39-5.05]; fully-adjusted OR 2.69 [1.02-7.11]). Compared to patients with tertile 1 of TyG index, the unadjusted and fully-adjusted OR for occurrence of carotid atherosclerosis were 4.64 (1.85-11.60) and 5.10 (1.54-16.93) in patients with tertile 3. Similarly, higher prevalent carotid artery plaque was observed with increasing TyG index (unadjusted OR 3.11 [1.54-6.26]; fully-adjusted OR 3.61 [1.15-11.38]) or with tertile 3 vs. tertile 1 (unadjusted OR 10.20 [2.83-36.82]; fully-adjusted OR 17.89 [2.88-111.11]). Additionally, TyG index provided incremental predictive capacity beyond established risk factors, shown by an increase in discrimination ability (all P &lt; 0.001). <h3>Conclusion</h3> TyG index was positively correlated with the burden of atherosclerosis in PsA patients, independent of traditional cardiovascular risk factors and psoriatic-related factors. These findings suggest that TyG index may be a promising atherosclerotic marker for PsA population. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1005 ASSOCIATION BETWEEN CHANGES IN SERUM ALKALINE PHOSPHATASE LEVELS AND RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS
Authors: T. H. Kim, S. Y. Park, J. H. Shin, S. Lee, K. B. Joo, B. S. Koo
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The changes in bone metabolism may occur earlier than those that can be identified on radiography. Although studies have evaluated the changes in inflammatory markers that precede radiographic progression, no studies have evaluated the relationship between the timing of changes in bone metabolism and radiographic progression in patients with AS. <h3>Objectives</h3> To determine the relationship between serum alkaline phosphatase levels and radiographic changes over time in ankylosing spondylitis. <h3>Methods</h3> This retrospective study evaluated the electronic medical records of patients with ankylosing spondylitis between January 2001 and December 2018. Longitudinal data including serum alkaline phosphatase levels were imputed by linear interpolation at 3-month intervals. Among the serum alkaline phosphatase levels for 8 years prior to measurement of the modified Stoke Ankylosing Spondylitis Spinal Score, the serum alkaline phosphatase level having the highest beta coefficient with the modified Stoke Ankylosing Spondylitis Spinal Score was selected. Linear mixed models with the selected serum alkaline phosphatase levels and the modified Stoke Ankylosing Spondylitis Spinal Score, including clinical variables, were investigated. <h3>Results</h3> Overall, 1122 patients were included, with a mean follow-up period of 8.20 (standard deviation: 2.85) years. Of the series of serum alkaline phosphatase levels, the level in the previous 5 years and 3 months showed the highest beta coefficient with the modified Stoke Ankylosing Spondylitis Spinal Score (Figure 1). In the linear mixed model including clinical variables, the serum alkaline phosphatase level 5 years and 3 months before radiographic changes was significantly associated with the modified Stoke Ankylosing Spondylitis Spinal Score (β=0.021, 95% confidence interval: 0.017–0.025, <i>p&lt;.</i>001). <h3>Conclusion</h3> Serum alkaline phosphatase levels measured at approximately 5 years before may be a surrogate marker for predicting spinal radiographic changes. Long-term prospective clinical and experimental studies of &gt; 5 years are required for biomarker discovery or therapeutic research on the radiographic progression of ankylosing spondylitis. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1155 SOLUBLE PROGRAMMED CELL DEATH-1 IN PSORIASIS AND PSORIATIC ARTHRITIS PATIENTS
Authors: S. A. A. Tabra, R. Elsharaby, E. S. E. Shaker, A. A. Moustafa, M. H. Abu-Zaid
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> psoriasis (PSO) and Psoriatic arthritis (PsA) are chronic, inflammatory, diseases that affect many sustems<sup>[1]</sup>. Soluble programmed cell death- 1 (sPD-1) block the PD-1/PD-L1 inhibitory pathway and associated with persistent activation of self-reactive T cells<sup>[2]</sup>. <h3>Objectives</h3> Assess the plasma levels of sPD-1 in PSO and PsA patients and correlate it with the clinical, laboratory, radiological characteristics and disease activity. <h3>Methods</h3> This study included 30 PSO patients (G I), 30 PsA patients (G II), and 40 healthy control (G III). All studied groups were subjected to clinical assessment, PASI and DAPSA scores assessment, musculoskeletal ultrasound (MSUS) assessment of affected areas, laboratory evaluation in form of CBC, ESR, and CRP. Plasma levels of sPD-1 were measured and correlated with different parameters. <h3>Results</h3> There were no significant differences between the three groups regarding demographic data (P&gt;0.05). 19 PSO patients were receiving biological treatment while 21 PsA patients were receiving biological therapy. The remaining patients were receiving conventional DMARDs. PASI score was 20.34± 8.63 &amp; 21.62± 10.53 in GI &amp; GII consequently with no significant difference between PSO &amp; PsA groups (P=0.6). DAPSA score was 10.28±5.39 in G II. Plasma levels of sPD-1 were 465.64±251.16, 786.44±153.96, and 198.73±73.36 in the three groups respectively with significant increase in GI, &amp; GII than controls (P&lt;0.01), sPD-1 was significantly elevated in PsA patients when compared with PSO patients (P&lt;0.01). s-PD-1 levels were elevated in patients who had active synovitis by MSUS. s-PD-1 levels were positively correlated with CRP, PASI score, and DAPSA score. Figure 1 demonstrates sPD-1 levels in the three groups. <h3>Conclusion</h3> Plasma levels of sPD-1 were elevated in PSO and PsA patients and correlated with disease severity and activity. sPD-1 might be good predictor of PSO and PsA disease activity, a new biomarker or target for immunomodulatory therapy. <h3>References</h3> [1]El Miedany, Y., El Gaafary, M., GadAllah, N. <i>et al.</i> Psoriatic arthritis treatment to the target: a consensus, evidence-based clinical practice recommendations for the management of psoriatic arthritis and its concomitant clinical manifestations. <i>Egypt Rheumatol Rehabil</i>. 2022; 49, 32. [2]Greisen SR, Rasmussen TK, Stengaard-Pedersen K, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol. 2014; 43(2):101-108. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0951 EFFICACY AND SAFETY OF UPADACITINIB IN ANKYLOSING SPONDYLITIS. REAL WORLD DATA
Authors: C. Merino Argumánez, C. Secada-Gómez, C. Vergara, A. Urruticoechea-Arana, S. Alonso Castro, M. L. García-Vivar, M. Moreno, R. Almodovar González, R. Blanco, J. Sanz
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Upadacitinib is a selective and reversible inhibitor of Janus Kinases (JAKs) that preferentially inhibits signaling via JAK1 or JAK1/3. JAK1 inhibition with upadacitinib modulates JAK-dependet cytokine signaling, thereby decreasing the inflammatory burden of different immune-mediated diseases. Upadacitinib is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis (radiographic axial spondyloarthritis), ulcerative colitis, and atopic dermatitis. In the case of ankylosing spondylitis, the drug has been approved for use in Spain since March 2022. <h3>Objectives</h3> The present study aims to evaluate the first data on safety and efficacy of upadacitinib use in ankylosing spondylitis in real clinical practice. <h3>Methods</h3> Retrospective observational multicenter study that included patients of 8 Spanish hospitals. Demographic data, personal history, and clinical course of patients diagnosed with ankylosing spondylitis treated with upadacitinib at participating centers were collected. <h3>Results</h3> Forty-four patients with ankylosing spondylitis who received upadacitinib for a mean time (SD) of 8.7 (7.4) months were included in the study. They had received previous biological treatments in 86 % of cases, 30% of patients at least 5. An improvement was observed in 70 % of patients as measured by subjective patient-reported improvement. The treatment was suspended in the 27.3% of patients, the main reason for suspension was inefficacy. A higher percentage of suspension was found in patients who had received a greater number of previous biological treatments. Adverse effects were reported in 8 patients, the most serious being one episode of tachyarrhythmia, one episode of deep vein thrombosis, one episode of peptic ulcer and one episode of herpes zoster, and the most frequent adverse effect being headache. <h3>Conclusion</h3> 70% of patients with ankylosing spondylitis who received upadacitinib for a median time of 8.7 months experienced subjective improvement in their symptoms. <h3>Acknowledgements</h3> Acknowledgements to all collaborators. <h3>Disclosure of Interests</h3> None Declared.